A prospective study on the natural history of multiple sclerosis: Clues to the conduct and interpretation of clinical trials

Journal of the Neurological Sciences

Volumn 168, Issue 2, 1999, Pages 96-106

  Amato, Maria Pia ^a   Ponziani, Giuseppina ^a   Bartolozzi, Maria Letizia ^a   Siracusa, Gianfranco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clinical trials; Multiple sclerosis; Natural history

Indexed keywords

ARTICLE; DISEASE COURSE; HISTORY; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CLINICAL TRIALS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0032834160     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00143-4     Document Type: Article

References (35)

1. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
2. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
3. Schumacher G.A., Beebe G., Kibler R.F., et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci. 122:1965;552-568.
4. Amato M.P., Hours M., Bartolozzi M.L., Cortinovis P., Confavreux C. for the EVALUED Group. Cross-national standardization in describing the natural history of multiple sclerosis: the European experience with the EDMUS database system. Neurology. 46:(29):1996;123.
5. Paty D.W., Oger J.J.F., Kastrukoff L.F., et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 38:1988;180-184.
6. Norosis M.J. SPSS/PC+ Version 4.0 Statistics for the IBM PC/XT/AT and PS/2. III :1990;SPSS Inc, Chicago.
7. McAlpine D. The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain. 84:1961;186-203.
8. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 103:1980;281-300.
9. Compston A., Ebers G., Lassmsnn H., McDonald I., Matthews B., Wekerle H. Natural history of multiple sclerosis. Compston A. McAlpine's Multiple Sclerosis. Third Edition :1998;191-221 Churchill Livingstone, London.
10. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 116:1993;117-134.
11. Weinshenker B.G., Bass B., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain. 112:1989;133-146.
12. Weinshenker B.G., Bass B., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 2. Predictive value of the early clinical course. Brain. 112:1989;1419-1428.
13. Weinshenker B.G., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 3. Multivariate analysis of predictive factors and models of outcome. Brain. 114:1991;1045-1056.
14. Weinshenker B.G., Rice G.P.A., Noseworthy J., Carriere W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 4. Applications to planning and interpretation of clinical trials. Brain. 114:1991;1057-1067.
15. Amato M.P., Fratiglioni L., Groppi C., Siracusa G., Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. 45:1988;746-748.
16. Amato M.P., Groppi C., Siracusa G.F., Fratiglioni L. Inter- and intra-observer reliability in Kurtzke scoring systems in multiple sclerosis. Ital J Neurol Sci. Suppl.6:1987;129-132.
17. Francis D.A., Bain P., Swan A.V., Hughes R.A.C. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 48:1991;299-301.
18. Goodkin D.E., Cookfair D., Wende K., et al. Inter- and intra-rater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology. 42:1992;859-863.
19. Noseworthy J.H., Vandervoort M.K., Wong C.J., Ebers G.C. Inter-rater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology. 40:1990;971-975.
20. Cole S.R., Beck R.W., Moke P.S., Kaufman D.I., Tourtellotte W.W. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology. 51:1998;885-887.
21. Paolino E., Fainardi E., Ruppi P., et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry. 60:1996;572-575.
22. Sharief M.K., Thompson E.J. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol. 29:1991;147-151.
23. Solderstrom M., Ya-Ping J., Hillert J., Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 50:1998;708-714.
24. Frederiksen J.L., Larsson H.B., Olesen J. Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand. 86:1992;317-322.
25. Rocchelli P., Poloni M., Mazzarello P., Delodovici M. Clinical and CSF findings in multiple sclerosis patients with or without IgG oligoclonal bands at isoelectric focusing examination of CSF and serum proteins. Eur Neurol. 22:1983;35-42.
26. Verjans E., Theys P., Delmotte P., Carton H. Clinical parameters and intrathecal IgG synthesis as prognostic features in multiple sclerosis. Part I. J Neurol. 229:1983;155-165.
27. Ford B., Tampieri D., Francis G. Long term follow up of acute transverse partial myelopathy. Neurology. 42:1992;250-252.
28. Jacobs L., Munschauer F.E., Kaba S.E. Clinical and magnetic resonance imaging in optic neuritis. Neurology. 41:1991;15-19.
29. Lee K.H., Hashimoto S.A., Hooge J.P., et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 41:1991;657-660.
30. Morrissey S.P., Miller D.H., Kendall B.E., et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain. 116:1993;135-146.
31. Filippi M., Paty D.W., Kappos L., et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 45:1995;255-260.
32. Khoury S.J., Guttmann C.R.G., Orav E.J., et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 44:1994;2120-2124.
33. Smith M.E., Stone L.A., Albert P.S., et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine enhancing magnetic resonance imaging lesions. Ann Neurol. 33:1993;480-489.
34. Goodkin D.E., Hertsgaard D., Rudik R.A. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis: implications for clinical trials. Arch Neurol. 46:1989;1107-1112.
35. Weinshenker B.G., Issa M., Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive multiple sclerosis. Neurology. 46:1996;1613-1619.